Safety and Efficacy Study of SAR442720 in Combination With Other Agents in Advanced Malignancies
-
- STATUS
- Recruiting
-
- End date
- Jul 15, 2025
-
- participants needed
- 133
-
- sponsor
- Sanofi
Summary
Primary Objectives:
- Part 1
- To characterize the safety and tolerability of SAR442720 in combination with pembrolizumab in participants with advanced solid tumors.
- To define the MTD and RP2D for the combination of SAR442720 and pembrolizumab in participants with solid tumors.
- Part 2
- To determine the anti-tumor activity of SAR442720 in combination with pembrolizumab.
- Part 3A
- To define the MTD and RP2D for the combination of SAR442720 and adagrasib in participants with KRAS G12C NSCLC
- To characterize the safety and tolerability of SAR442720 in combination with adagrasib in participants with KRAS G12C NSCLC
- Part 3B
- To determine the anti-tumor activity of SAR442720 in combination with adagrasib in participants with KRAS G12C NSCLC
- Part 4
- To evaluate the impact of food on the PK of SAR442720 when dosed with pembrolizumab.
- To evaluate the impact of the formulations (formulation 1 and formulation 2) on the PK of SAR442720 when dosed with pembrolizumab.
Secondary Objectives:
- Part 1
- To assess the PK of SAR442720 with pembrolizumab, and the PK of pembrolizumab with SAR442720.
- To estimate the anti-tumor effects of SAR442720 with pembrolizumab.
- Part 2
- To assess the safety profile of SAR442720 combined with pembrolizumab.
- To assess other indicators of anti-tumor activity.
- To assess the PK of SAR442720 with pembrolizumab, and the PK of pembrolizumab with SAR442720.
- Part 3A
- To characterize the PK of SAR442720 with adagrasib, and the PK of adagrasib with SAR442720.
- To estimate the anti-tumor effects of SAR442720 with adagrasib
- Part 3B
- To assess the safety profile of SAR442720 with adagrasib in participants with KRAS G12C NSCLC.
- To assess other indicators of anti-tumor activity.
- To assess the PK of SAR442720 with adagrasib, and the PK of adagrasib with SAR442720.
- Part 4
- To assess the safety and tolerability of SAR442720 formulations with pembrolizumab
- To estimate the anti-tumor effects of SAR442720 with pembrolizumab.
Description
This open label Phase 1 multicenter study is designed to evaluate the safety and maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of SAR442720 in combination with pembrolizumab in participants with solid tumors in Part 1.
In Part 2, in the expansion cohort (Cohort A) we will assess the antitumor activity and safety of SAR442720 combined with pembrolizumab in participants with metastatic 1L lung cancer.
In Part 3, we will evaluate the safety, MTD, RP2D and antitumor activity of SAR442720 in combination with adagrasib in participants with lung cancer and KRAS G12C mutation.
In Part 4, we will evaluate the impact of the formulations (formulation 1 and formulation 2) and of the food on the PK of SAR442720 when dosed in combination with pembrolizumab. The expected duration of study intervention for participants may vary, based on progression date; median expected duration of study per participant is estimated to be about 10 months in Part 1, Part 3 and Part 4 (up to 1 month for screening, a median of 6 months for treatment, and a median of 3 months for long term follow-up) and in Part 2 16 months (up to 1 month for screening, a median of 12 months for treatment and a median of 3 months for long term follow up.)
Details
| Condition | Metastatic Neoplasm |
|---|---|
| Treatment | Pembrolizumab, SAR442720, Adagrasib |
| Clinical Study Identifier | NCT04418661 |
| Sponsor | Sanofi |
| Last Modified on | 21 July 2022 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer